Homologous recombination deficiency due to mutational inactivation of the BRCA1 and BRCA2 tumor suppressor genes is known to make human tumors susceptible to PARP inhibitors and platinum-based chemotherapies (65). Here, BRCA2 is linked to neoplasm.